PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CR UK calls on Scottish gov to ‘urgently’ restart cancer trials

Cancer Research UK is urging Scotland’s government and health service providers to restart existing clinical trials for cancer as quickly as possible, following a 95% drop in new patients entering trials among the pandemic.

Almost all clinical research trials in Scotland have been paused in response to COVID-19, thus removing innovative treatment options for many people living with cancer, a report to MSPs and charities also found.

The Scottish government must boost coronavirus testing so that patients can participate in clinical trials safely and be treated in safe spaces where there is minimal risk of exposure to the virus, the charity noted.

“Cancer hasn’t stopped because of the pandemic and it’s essential that clinical trials are restarted urgently,” said Marion O’Neill, Cancer Research UK’s head of external affairs in Scotland. “The Scottish Government and health boards, together with NHS Research Scotland, needs to move fast to get existing cancer clinical trials that provide a lifeline to patients and their families restarted.

“Clinical trials are such an important part of our armoury. For some of our patients with ovarian cancer, it’s the last option for them,” added Professor Charlie Gourley is Clinical Director at the Cancer Research UK Edinburgh Centre.

“So many trials are successful now that the pause has taken away hope for some patients when they know that they would be offered a trial under normal circumstances but, because of coronavirus, trials have been closed to new patients. This has been incredibly hard for patients.”

The Cross Party Group on Cancer are considering findings of the report, which also assessed the impact of the pandemic on cancer diagnosis, treatment and care.

Cancer Research UK recently highlighted concerns about the impact of COVID-19 on the future of cancer research, announcing that it might be forced to cut £150 million a year from its research funding because of a sharp drop in income caused by the pandemic.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026